On June 27, 2022, under the guidance of the China Association for Science and Technology, the Hangzhou Municipal People's Government, the Zhejiang Provincial Committee of the Democratic National Construction Association, and the China Investment Development Promotion Association jointly hosted the "Sixth All Things Growth Conference" in Hangzhou. The "2022 Hangzhou Unicorn & Quasi-Unicorn Enterprise List" was released at the meeting, and Hopstem successfully won the title of "Quasi-Unicorn Enterprise".
As a leading company in the iPSC cell therapy industry, Hopstem stands out with its steady innovation and international leading technology platform and has been recognized and supported by various units and leaders in the industry to receive this honor.
Hopstem Wins the Third Prize of VB-Link Competition
Huayi List: Hopstem Ranks Top 10 Most Promising Biotech Companies
The iPSC-derived Human Forebrain Neural Progenitor Cell Injection hNPC01 of Hopstem has Received CDE's Clinical Implication Approval
The launch meeting of the clinical research project of Hopstem hNPC01 universal cell therapy product for the treatment of stroke sequelae was successfully held.